Across TCGA pan-cancer cohorts, LYPD1 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of LYPD1’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where LYPD1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LYPD1 is over-expressed in tumor, although a few such as OV show the opposite, repressed pattern.
LUAD and OV are the cancer types where LYPD1 tumor–normal differential expression is most reproducible.